DJS Antibodies

DJS Antibodies, headquartered in Oxford, UK, is a biotechnology company dedicated to developing the next generation of antibody therapies. DJS Antibodies leverages its proprietary HEPTAD platform to enable antibody discovery against GPCRs and other challenging targets. Using HEPTAD, the company has developed a unique pipeline, including DJS-002, a novel antibody targeting LPAR1 for the treatment of chronic fibrotic diseases.